We are live on ! Find out more

Drugs Made In America Acquisition Corp Units

DMAAU

Market cap $231M

11.30 USD

0.00

0%

At close Updated Oct 16, 4:00 PM EDT

1 day

0%

5 days

2.82%

1 month

2.82%

3 months

2.82%

6 months

3.67%

Year to date

7.62%

1 year

7.82%

5 years

13%

10 years

13%

About: Drugs Made In America Acquisition Corp is a blank check company.

Financials Shell Companies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 0%

Negative 0%

Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Fort Lauderdale, FL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) (the “Company”) announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “DMIIU” beginning September 25, 2025. Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols “DMII” and “DMIIR,” respectively. The underwriters have been granted a 45-day option to purchase up to an additional 7,500,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on September 26, 2025, subject to customary closing conditions.

Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Drugs Made in America Acquisition Corp. Announces Advisory Team

Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactively pursue the deliverable of a business or combinations that seeks to become a new competitive cost producer of drugs made in America. Onboarding production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America.

Drugs Made in America Acquisition Corp. Announces Advisory Team

See News Rankings

Price charts implemented using Lightweight Charts™